Marquest Medical
This article was originally published in The Gray Sheet
Executive Summary
Will shut down its Nogales, Mexico operations and integrate them into its central manufacturing facility in Englewood, Colorado. FDA cited the Mexican plant for GMP violations last July ("The Gray Sheet" Nov. 16, 1992, p. 5). The consolidation is part of a broad restructuring effort, which also included the sale of Marquest's Parker, Colorado facility in January and ongoing financing negotiations with Scherer Healthcare ("The Gray Sheet" Jan. 18, p. 15). The restructuring was undertaken to finance costs associated with an October 1991 consent decree that required the firm to cease U.S. operations until it could demonstrate compliance with GMPs. The revalidation and product reintroduction process "is now essentially complete," Marquest says.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.